This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects

Inclusion Criteria:

• Body mass index (BMI): 18 to 27 kg/m 2
• Female subjects must be postmenopausal for at least 1 year, surgically sterile, or using a reliable method of contraception at screening.
• Male subjects must be willing to use accepted contraceptive methods, avoid unprotected sex, and donating sperm until 3 months after drug administration.

Exclusion Criteria:

• Clinically relevant disease and/or abnormalities (past or present)
• Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator
• Use of any prescription medication within 14 days of Day 1
• Use of over-the-counter (OTC) medication (with the exception of acetaminophen), vitamin/nutritional supplements and herbal preparations within 14 days of Day 1
• Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1